Literature DB >> 19903694

Differences in etiological and clinical manifestations in upper extremity and lower limb deep venous thrombosis patients from India.

Navin Pai1, Shrimati Shetty, Bipin Kulkarni, Kanjaksha Ghosh.   

Abstract

We assessed the clinical manifestations in upper and lower limb deep venous thrombosis patients from India and difference in etiological factors. Fifty-three patients with primary upper extremity deep vein thrombosis (UEDVT; males 30, females 23) and 236 patients with lower limb deep vein thrombosis (LLDVT; males 157, females 79) were included in this study. The thrombophilia markers studied were protein C (PC), protein S (PS), antithrombin (AT) III, and factor V Leiden (FVL) mutation. Females had significantly higher prevalence of prothrombotic markers as compared to males (P = .046) in the UEDVT group. No statistically significant differences in the prevalence of prothrombotic markers were observed between the LLDVT and the UEDVT patients. The clinical picture however revealed greater involvement of thrombus of the iliofemoral vein (P = .009) and the proximal tibial vein (P = .005) in males than females, while no differences were observed in the clinical manifestations between the 2 sexes in UEDVT patients. Our study is able to give a broad perspective of the prevalence data of UEDVT and LLDVT in the city of Mumbai of approximately 5 million population served by this hospital. We conclude that the topology of thrombosis in deep vein thrombosis (DVT) patients in India is different from that of the Western countries.

Entities:  

Mesh:

Year:  2009        PMID: 19903694     DOI: 10.1177/1076029609351290

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  1 in total

1.  Marburg I Polymorphism (G511E) in Adults with Deep Vein Thrombosis.

Authors:  Narender Kumar; Archana Sundaram; Neetu Rani; Jasmina Ahluwalia; Reena Das; Neelam Varma; Vikas Suri; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2019-06-12       Impact factor: 0.900

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.